KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Idexx Laboratories (IDXX) EBITDA Margin (2016 - 2026)

Idexx Laboratories has reported EBITDA Margin over the past 17 years, most recently at 28.94% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 152.0% year-over-year to 28.94%; the TTM value through Dec 2025 reached 31.6%, up 265.0%, while the annual FY2025 figure was 31.6%, 265.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 28.94% at Idexx Laboratories, down from 32.11% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 33.62% in Q2 2025 and troughed at 20.81% in Q2 2022.
  • A 5-year average of 29.25% and a median of 29.88% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -1057bps in 2022 and later skyrocketed 1058bps in 2023.
  • Year by year, EBITDA Margin stood at 24.86% in 2021, then rose by 10bps to 27.34% in 2022, then decreased by 0bps to 27.21% in 2023, then rose by 1bps to 27.42% in 2024, then rose by 6bps to 28.94% in 2025.
  • Business Quant data shows EBITDA Margin for IDXX at 28.94% in Q4 2025, 32.11% in Q3 2025, and 33.62% in Q2 2025.